In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Great Point Partners LLC reported 37 stock positions worth $424.4 million . Its top holding was Vor Biopharma (VOR) at 7.4% of the portfolio, followed by Abivax SA-ADR (ABVX, 6.4% ) and Vera Therapeutics (VERA, 6.1% ). Compared with Q1 2026, it opened 10 new positions, sold out of 12, added to 7 and reduced 9. The biggest buy was a new position in Abivax SA-ADR (ABVX) and the biggest sale an exit from Apogee Therapeutics (APGE).
Location Greenwich, CT
CIK 0001281446
Portfolio Value $424.4M (Q2 2026) Holdings 37 stocks · $424.4M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2026 VOR Vor Biopharma Inc. 1,700,000 $31.3M Reduce -2.9% ABVX Abivax SA-ADR 204,314 $27.2M New VERA Vera Therapeutics Inc. 600,836 $25.8M Add +201.4% ZURA Zura Bio Ltd. 4,215,930 $24.9M No change ALMS Alumis Inc. 856,061 $24.1M No change SLGL Sol-Gel Technologies Ltd. 274,363 $20.3M No change DFTX Definium Therapeutics Inc. 425,000 $20.0M New ANNX Annexon Inc. 3,500,000 $20.0M Add +40.0% ORKA Oruka Therapeutics Inc. 183,330 $17.4M No change MLTX Moonlake Immunotherapeutics 855,813 $16.7M Add +71.2% SGMT Sagimet Biosciences Inc. Class A 2,029,933 $15.7M New CTNM Contineum Therapeutics Inc. Class A 921,481 $15.1M Add +15.2% IMMX Immix Biopharma Inc. 1,277,642 $13.2M Add +265.0% CLYM Climb Bio Inc. 1,000,000 $13.0M Reduce -25.0% AMLX Amylyx Pharmaceuticals Inc. 700,000 $12.6M Reduce -60.0% NKTR Nektar Therapeutics 175,000 $12.2M Reduce -44.7% NGNE Neurogene Inc. 352,180 $11.1M Reduce -29.6% LBRX LB Pharmaceuticals Inc. 317,221 $10.3M Add +5.7% IRD Opus Genetics Inc. 1,970,187 $8.1M Add +507.4% EPRX Eupraxia Pharmaceuticals Inc. 1,200,000 $7.9M No change DRUG Bright Minds Biosciences Inc. 109,603 $7.7M Reduce -50.2% IFRX Inflarx NV 3,046,557 $6.8M New RLMD Relmada Therapeutics Inc. 842,106 $5.8M No change JATT Jatt II Acquisition Corp. 500,000 $5.7M New CGEM Cullinan Therapeutics Inc. 300,000 $5.5M No change ALT Altimmune Inc. 1,741,232 $5.3M New AMAN Amanat Acquisition Corp. Class A 500,000 $5.1M New RZLT Rezolute Inc. 951,809 $4.9M No change SLN Silence Therapeutics PLC-ADR 450,000 $4.9M Reduce -55.9% PALI Palisade Bio Inc. 2,284,819 $4.8M Reduce -32.9% EVMN Evommune Inc. 325,000 $4.3M No change SCYX Scynexis Inc. 944,292 $3.8M No change ELVN Enliven Therapeutics Inc. 70,000 $3.6M New HUMA Humacyte Inc. 3,750,000 $2.9M No change RNTX Rein Therapeutics Inc. 2,575,000 $2.7M New DBVT DBV Technologies SA-Spon ADR 156,906 $2.6M New PMN Promis Neurosciences Inc. 86,150 $1.1M Reduce -76.8%
Options reported separately and not counted above: ABVX calls ($53.3M), IBRX puts ($26.3M), RARE puts ($20.0M), GALT calls ($3.7M), AVXL calls ($1.4M).
Portfolio Sells Q1 2026 → Q2 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▲ APGE Apogee Therapeutics Inc. Sold out 0.00% −7.71 KALV Kalvista Pharmaceuticals Inc. Sold out 0.00% −3.33 IMVT Immunovant Inc. Sold out 0.00% −3.32 JBIO Jade Biosciences Inc. Sold out 0.00% −3.32 AMLX Amylyx Pharmaceuticals Inc. Reduce -60.0% 2.96% −3.00 NKTR Nektar Therapeutics Reduce -44.7% 2.88% −2.70 ZBIO Zenas Biopharma Inc. Sold out 0.00% −2.51 DRUG Bright Minds Biosciences Inc. Reduce -50.2% 1.81% −2.12 CMPX Compass Therapeutics Inc. Sold out 0.00% −1.75 CNTX Context Therapeutics Inc. Sold out 0.00% −1.44 UNCY Unicycive Therapeutics Inc. Sold out 0.00% −1.28 TENX Tenax Therapeutics Inc. Sold out 0.00% −1.28 PMN Promis Neurosciences Inc. Reduce -76.8% 0.27% −0.89 PHVS Pharvaris NV Sold out 0.00% −0.57 AVTX Avalo Therapeutics Inc. Sold out 0.00% −0.46 ALKS Alkermes PLC Sold out 0.00% −0.43 PALI Palisade Bio Inc. Reduce -32.9% 1.13% −0.33 VOR Vor Biopharma Inc. Reduce -2.9% 7.37% −0.27 SLN Silence Therapeutics PLC-ADR Reduce -55.9% 1.16% −0.15 NGNE Neurogene Inc. Reduce -29.6% 2.61% +0.14 CLYM Climb Bio Inc. Reduce -25.0% 3.07% +0.83
Portfolio Buys Q1 2026 → Q2 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2026 % Of Portfolio Change To Portfolio ▼ ABVX Abivax SA-ADR New 6.41% +6.41 DFTX Definium Therapeutics Inc. New 4.71% +4.71 VERA Vera Therapeutics Inc. Add +201.4% 6.07% +4.11 SGMT Sagimet Biosciences Inc. Class A New 3.70% +3.70 IMMX Immix Biopharma Inc. Add +265.0% 3.10% +2.32 MLTX Moonlake Immunotherapeutics Add +71.2% 3.93% +1.64 IFRX Inflarx NV New 1.61% +1.61 IRD Opus Genetics Inc. Add +507.4% 1.91% +1.55 JATT Jatt II Acquisition Corp. New 1.34% +1.34 ANNX Annexon Inc. Add +40.0% 4.71% +1.32 ALT Altimmune Inc. New 1.25% +1.25 AMAN Amanat Acquisition Corp. Class A New 1.20% +1.20 CTNM Contineum Therapeutics Inc. Class A Add +15.2% 3.56% +1.00 ELVN Enliven Therapeutics Inc. New 0.84% +0.84 RNTX Rein Therapeutics Inc. New 0.63% +0.63 LBRX LB Pharmaceuticals Inc. Add +5.7% 2.43% +0.61 DBVT DBV Technologies SA-Spon ADR New 0.61% +0.61
Options Activity Q1 2026 → Q2 2026 Security Type Change vs Q1 2026 Underlying Shares Value ▼ ABVX Abivax SA-ADR call New 400,000 $53.3M RARE Ultragenyx Pharmaceutical Inc. put New 600,000 $20.0M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 37 $424.4M VOR, ABVX, VERA, ZURA, ALMS Q1 2026 39 $408.3M APGE, VOR, ZURA, AMLX, NKTR Q4 2025 29 $308.4M APGE, AMLX, ZURA, IRON, RAPT Q3 2025 28 $239.5M AMLX, RZLT, NKTR, ZURA, SLNO Q2 2025 26 $153.8M IONS, RZLT, AMLX, LEGN, ABVX Q1 2025 31 $184.0M CYTK, KALV, EOLS, ABVX, VRDN Q4 2024 26 $212.2M IONS, CYTK, KALV, VRDN, PLRX Q3 2024 29 $331.4M NGNE, ABVX, PLRX, EOLS, VRDN Q2 2024 33 $522.0M URGN, NGNE, ABVX, MRUS, PLRX Q1 2024 35 $641.6M NGNE, ALPN, URGN, ABVX, EOLS